Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Mar 16, 2023 · 10-K · 75 days after period end · 0001628280-23-008315
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $71.42M | $52.30M | — | — |
| Net Income | -$11.01M | -$10.06M | -$8.04M | -$2.30K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 16, 2023 · 75 d after period end
